Afficher la notice abrégée

Mature tertiary lymphoid structures predict immune checkpoint inhibitor efficacy in solid tumors independently of PD-L1 expression

dc.rights.licenseopenen_US
dc.contributor.authorVANHERSECKE, Lucile
dc.contributor.authorBRUNET, Maxime
dc.contributor.authorGUEGAN, Jean-Philippe
dc.contributor.authorREY, Christophe
dc.contributor.authorBOUGOUIN, Antoine
dc.contributor.authorCOUSIN, Sophie
dc.contributor.authorLE MOULEC, Sylvestre
dc.contributor.authorBESSE, Benjamin
dc.contributor.authorLORIOT, Yohann
dc.contributor.authorLARROQUETTE, Mathieu
dc.contributor.authorSOUBEYRAN, Isabelle
dc.contributor.authorTOULMONDE, Maud
dc.contributor.authorROUBAUD, Guilhem
dc.contributor.authorPERNOT, Simon
dc.contributor.authorCABART, Mathilde
dc.contributor.authorCHOMY, Francois
dc.contributor.authorLEFEVRE, Corentin
dc.contributor.authorBOURCIER, Kevin
dc.contributor.authorKIND, Michele
dc.contributor.authorGIGLIOLI, Ilenia
dc.contributor.authorSAUTES-FRIDMAN, Catherine
dc.contributor.authorVELASCO, Valerie
dc.contributor.authorCOURGEON, Felicie
dc.contributor.authorOFLAZOGLU, Ezoglin
dc.contributor.authorSAVINA, Ariel
dc.contributor.authorMARABELLE, Aurelien
dc.contributor.authorSORIA, Jean-Charles
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorBELLERA, Carine
dc.contributor.authorSOFEU, Casimir
dc.contributor.authorBESSEDE, Alban
dc.contributor.authorFRIDMAN, Wolf H.
dc.contributor.authorLE LOARER, Francois
dc.contributor.authorITALIANO, Antoine
dc.date.accessioned2022-03-09T15:19:42Z
dc.date.available2022-03-09T15:19:42Z
dc.date.issued2021
dc.identifier.issn2662-1347 (Electronic) 2662-1347 (Linking)en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/136408
dc.description.abstractEnOnly a minority of patients derive long-term clinical benefit from anti-PD1/PD-L1 monoclonal antibodies. The presence of tertiary lymphoid structures (TLS) has been associated with improved survival in several tumor types. Here, using a large-scale retrospective analysis of three independent cohorts of cancer patients treated with anti-PD1/PD-L1 antibodies, we showed that the presence of mature TLS was associated with improved objective response rate, progression-free survival, and overall survival independently of PD-L1 expression status and CD8+ T-cell density. These results pave the way for using TLS detection to select patients who are more likely to benefit from immune checkpoint blockade.
dc.language.isoENen_US
dc.title.enMature tertiary lymphoid structures predict immune checkpoint inhibitor efficacy in solid tumors independently of PD-L1 expression
dc.typeArticle de revueen_US
dc.identifier.doi10.1038/s43018-021-00232-6en_US
dc.subject.halSciences du Vivant [q-bio]/Santé publique et épidémiologieen_US
dc.identifier.pubmed35118423en_US
bordeaux.journalNature Canceren_US
bordeaux.page794-802en_US
bordeaux.volume2en_US
bordeaux.hal.laboratoriesBordeaux Population Health Research Center (BPH) - UMR 1219en_US
bordeaux.issue8en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.institutionINSERMen_US
bordeaux.teamEPICENE_BPHen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
bordeaux.identifier.funderIDAstraZenecaen_US
hal.identifierhal-03603101
hal.version1
hal.date.transferred2022-03-09T15:19:46Z
hal.exporttrue
dc.rights.ccPas de Licence CCen_US
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Nature%20Cancer&rft.date=2021&rft.volume=2&rft.issue=8&rft.spage=794-802&rft.epage=794-802&rft.eissn=2662-1347%20(Electronic)%202662-1347%20(Linking)&rft.issn=2662-1347%20(Electronic)%202662-1347%20(Linking)&rft.au=VANHERSECKE,%20Lucile&BRUNET,%20Maxime&GUEGAN,%20Jean-Philippe&REY,%20Christophe&BOUGOUIN,%20Antoine&rft.genre=article


Fichier(s) constituant ce document

FichiersTailleFormatVue

Il n'y a pas de fichiers associés à ce document.

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée